Nearly one in four cancer drug packs in the NPPA’s revised price list will see no reduction in MRP, even as the overall average cut across 643 packs is 38.22%. Several high-cost patented medicines remain unchanged, prompting patient advocates to question how much relief the trade-margin cap will actually deliver when the new prices take effect on November 9.